Edgewise Therapeutics Inc is a biotechnology company focused on developing innovative treatments for muscle disorders, particularly those characterized by muscle weakness and atrophy
The company leverages its expertise in drug development to create novel therapeutic candidates that target underlying biological pathways involved in muscle function. By combining cutting-edge science with patient-focused approaches, Edgewise aims to address critical unmet medical needs in the realm of neuromuscular diseases, ultimately striving to improve the quality of life for patients affected by these conditions.
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT pressure gradient and NT-proBNP levels.
Shares of TransCode Therapeutics, Inc. (NASDAQRNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
